A wake-like state in vitro induced by transmembrane TNF/soluble TNF receptor reverse signaling

• Published in: Brain, behavior, and immunity Vol. 94; pp. 245 - 258
• Main Authors: Dykstra-Aiello, Cheryl, Koh, Khia Min Sabrina, Nguyen, Joseph, Xue, Mengran, Roy, Sandip, Krueger, James M.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.05.2021
• Subjects: Animals; Brain development; Cytokine; Female; In vitro sleep; Interleukin-1; Local sleep; Male; Mice; Neuroglia; Neurons; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Reverse signaling; Signal Transduction; Sleep; Tissue culture; TNF; TNF receptor; Tumor necrosis factor; Tumor Necrosis Factor-alpha; Wake; Interleukin-1; Sleep; Tumor necrosis factor; Brain development; Cytokine; Tissue culture; TNF receptor; Local sleep; Reverse signaling; TNF; Wake; In vitro sleep
• ISSN: 0889-1591; 1090-2139
• DOI: 10.1016/j.bbi.2021.01.036

•Emergent electrophysiology develops faster in vitro in absence of TNF or TNFRs.•Soluble TNFR1 treatment in vitro induces wake-like states in TNFKO and TNFRKO cells.•TNF forward/reverse signals to sleep/wake concur with other opposing TNF actions. Tumor necrosis factor alpha (TNF) has sleep regulatory and brain development roles. TNF promotes sleep in vivo and in vitro while TNF inhibition diminishes sleep. Transmembrane (tm) TNF and the tmTNF receptors (Rs), are cleaved by tumor necrosis factor alpha convertase to produce soluble (s) TNF and sTNFRs. Reverse signaling occurs in cells expressing tmTNF upon sTNFR binding. sTNFR administration in vivo inhibits sleep, thus we hypothesized that a wake-like state in vitro would be induced by sTNFR-tmTNF reverse signaling. Somatosensory cortical neuron/glia co-cultures derived from male and female mice lacking both TNFRs (TNFRKO), or lacking TNF (TNFKO) and wildtype (WT) mice were plated onto six-well multi-electrode arrays. Daily one-hour electrophysiological recordings were taken on culture days 4 through 14. sTNFR1 (0.0, 0.3, 3, 30, 60, and 120 ng/µL) was administered on day 14. A final one-hour recording was taken on day 15. Four measures were characterized that are also used to define sleep in vivo: action potentials (APs), burstiness index (BI), synchronization of electrical activity (SYN), and slow wave power (SWP; 0.25–3.75 Hz). Development rates of these emergent electrophysiological properties increased in cells from mice lacking TNF or both TNFRs compared to cells from WT mice. Decreased SWP, after the three lowest doses (0.3, 3 and 30 ng/µL) of the sTNFR1, indicate a wake-like state in cells from TNFRKO mice. A wake-like state was also induced after 3 ng/µl sTNFR1 treatment in cells from TNFKO mice, which express the TNFR1 ligand, lymphotoxin alpha. Cells from WT mice showed no treatment effects. Results are consistent with prior studies demonstrating involvement of TNF in brain development, TNF reverse signaling, and sleep regulation in vivo. Further, the current demonstration of sTNFR1 induction of a wake-like state in vitro is consistent with the idea that small neuronal/glial circuits manifest sleep- and wake-like states analogous to those occurring in vivo. Finally, that sTNF forward signaling enhances sleep while sTNFR1 reverse signaling enhances a wake-like state is consistent with other sTNF/tmTNF/sTNFR1 brain actions having opposing activities.